This comprehensive report from VPGMarketResearch.com contains 350 pages, 22 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities during the next five years. ..."
This new comprehensive report from VPGMarketResearch.com contains 225 pages and 5 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities during the next five years.
This new report from VPGMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging ..."
This new report from VPGMarketResearch provides granular analysis of the Kenya diagnostic testing market, including the 2016-2021 volume and sales forecasts by test for the following market segments:
- Cancer Diagnostics
BMI View: It is vital that companies that are looking to sell non-communicable disease therapeutics work
alongside the public sector and focus on physician education and patient awareness in a market that has
traditionally focussed on infectious diseases such as malar ..."
BMI View: Many emerging market economies are increasingly exposed to the negative effect of sustained
lower commodity prices. This is putting downward pressure on government finances and, as a consequence,
healthcare budgets. We nevertheless maintain a positive long-t ..."
BMI View: Drugmaker revenue earning opportunities in Kenya will continue to be restricted. Some
progress has been made towards addressing equity challenges, but universal coverage - and subsequently a
decline in the reliance of out-of-pocket spending - will not be ach ..."
BMI View: We expect Kenya to be the fastest market in Africa and the third fastest in the Middle East &
Africa region over the 2014-2019 period, with growth being driven by good economic performance and
increasing health expenditure. Almost all medical devices are imp ..."
BMI View: While Kenya's underdeveloped healthcare infrastructure is not conducive to clinical trials (only
14 clinical trials were registered in 2014), the country, as with other markets in the region, can offer
numerous benefits to drugmakers looking to conduct clini ..."
BMI View: Our outlook for Kenya's pharmaceutical expenditure is positive and will be driven by expanding
national health insurance coverage and improving public healthcare provision. While the Kenyan
government is focused on improving its population's access to health ..."